WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according to a post-hoc analysis of the phase III ESSENCE trial.

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this result using insurance claims data.

Oral semaglutide improved glycemic parameters and cardiovascular risk factors for adults with overweight or obesity, with greater improvements for those with weight loss of 15% or more, according to a post hoc analysis of OASIS-4.

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | Innovent's Eli Lilly-partnered mazdutide,

Adults with obesity lose more weight with semaglutide than with placebo (a sham medication). However, the risk of unwanted events is probably higher than with placebo after 24 months. Semaglutide makes little to no difference — or has uncertain effects — on quality of life, major cardiovascular events and death.

Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting® 2025 Across

A drug most often prescribed for diabetes and obesity might soon be prescribed to curb one of the world’s hardest to quit addictions. Scientists in Sweden and the US found that semaglutide, the active ingredient in Ozempic and Wegovy,

Alabama Attorney General Steve Marshall has shut down a Cullman IV clinic after allegations it gave patients unsafe, research-only weight loss drugs.